VRTX Casgevy 18 Months: 500 Patients, $43M Revenue

Casgevy (exagamglogene autotemcel) was supposed to be the moment CRISPR went from science project to commercial product. FDA approved it for sickle cell disease on December 8, 2023, the first CRISPR-edited therapy ever approved (FDA announcement). Eighteen months and a pediatric label expansion later, the commercial story is more interesting than the science.

Vertex Pharmaceuticals (VRTX) closed July 24 at $477.36, giving it a market cap near $123 billion. CRISPR Therapeutics (CRSP), the gene-editing pioneer that invented the platform and holds 40% of Casgevy economics, closed at $46.54 the same day, a $4.2 billion market cap. The gap between those two numbers is the entire investment thesis for both stocks. Let me break down what the actual revenue, patient, and treatment-center data say about whether that gap is justified.

If you are new to biotech catalysts, our guide to investing in biotech stocks explains the approval-to-revenue cycle in more depth, and our PDUFA date explainer covers how these FDA decisions get scheduled.

The Approval Recap

Casgevy is an autologous CD34+ hematopoietic stem cell therapy edited with CRISPR/Cas9 to disrupt the BCL11A erythroid enhancer, which switches the body back to producing fetal hemoglobin (HbF). The mechanism is elegant. Patients undergo apheresis to collect stem cells, those cells are shipped to a manufacturing facility for CRISPR editing over several weeks, the patient receives myeloablative busulfan conditioning chemotherapy, and then the edited cells are reinfused to engraft. Total timeline from start to finish: two to three months. This is a bone marrow transplant equivalent, not a pill.

The FDA approved Casgevy for SCD in December 2023 and for transfusion-dependent beta-thalassemia (TDT) in January 2024. The EMA approved both indications. Most recently, in June 2026, the FDA expanded the SCD label to children ages 2 to 11, which we covered in our Casgevy pediatric approval analysis. That expansion matters because it roughly doubles the addressable patient population, but it also adds a pediatric safety layer to an already complex treatment process.

The Commercial Reality

Here is where the headline narrative and the numbers diverge. As of Vertex’s most recent disclosures, more than 500 people globally have initiated the Casgevy treatment journey (CRISPR Therapeutics Q1 2026 update). That sounds impressive until you break it down. Approximately 300 patients have been referred to Authorized Treatment Centers (ATCs). About 165 have completed their first cell collection. Only 39 have actually received infusions across all regions.

Let me contextualize those numbers. The addressable market Vertex cites is more than 60,000 eligible patients across approved regions, including roughly 37,000 in North America and Europe and over 23,000 in the Middle East. In the US alone, severe SCD affects an estimated 16,000 to 20,000 patients, with about 100,000 total SCD patients. TDT adds another 1,500 domestically. Casgevy is treating 39 patients out of a 60,000-person addressable market, 18 months after approval.

The funnel attrition is the story. Of 500 who initiated, 300 were referred to ATCs, 165 collected cells, and 39 were infused. That is a 7.8% conversion from initiation to infusion. The treatment process is the bottleneck. Apheresis takes time. Manufacturing takes weeks. Myeloablative conditioning requires hospitalization and recovery. Each ATC can only process a limited number of patients per year, and Casgevy can only be administered at certified centers. As of mid-2026, the US ATC network remains concentrated at roughly 50 to 60 sites.

For investors tracking binary regulatory events, our piece on accelerated approval pathways explains how the FDA uses surrogate endpoints to bring therapies like this to market faster, and our complete response letter explainer covers what happens when the FDA needs more data before approval.

The Revenue Numbers

Casgevy generated $42.9 million in Q1 2026 revenue, up from $14.2 million in the prior-year quarter. That is a 3x year-over-year increase, and it beat the run rate from late 2025. Vertex also reported that Casgevy and its newly approved non-opioid pain therapy Journavx together delivered more than 25% of the company’s growth in Q1 2026.

But scale matters. Vertex’s Q1 2026 total revenue was roughly $2.96 billion, dominated by the cystic fibrosis franchise Trikafta/Kaftrio. Casgevy’s $42.9 million represents about 1.4% of total revenue. At a $2.2 million list price per patient, $42.9 million implies roughly 20 patients were recognized as revenue in the quarter. That is consistent with the 39 cumulative infusions, given the lag between infusion and revenue recognition under outcomes-based payer agreements.

Vertex projects combined Casgevy and Journavx revenue of $500 million for 2026, a 185% increase year-over-year. William Blair has modeled Casgevy alone at $344 million for 2026, with $212 million going to Vertex and $132 million to CRISPR Therapeutics under the 60/40 economic split. Even hitting that target, Casgevy would represent roughly 4 to 5% of Vertex’s total revenue. For CRISPR Therapeutics, it would be the majority of the company’s revenue.

Q2 2026 earnings are scheduled for August 3. That report will be the next real data point on whether the 500-patient initiation funnel is converting into recognized revenue fast enough to justify the 2026 guidance.

The Competitive Picture

Bluebird Bio’s Lyfgenia (lovotibeglogene autotemcel) was approved for SCD the same day as Casgevy. It uses lentiviral gene addition rather than CRISPR editing, targets the HBB gene directly rather than BCL11A, and carries a $3.1 million list price versus Casgevy’s $2.2 million. Bluebird has struggled even more than Vertex with the launch. The company has faced slow uptake, restructured its operations, and dealt with loan covenant pressure that threatened its cash runway into early 2026.

The competitive dynamic is counterintuitive. Casgevy is winning the head-to-head, but the entire gene-therapy segment is underperforming relative to pre-launch expectations. The pattern matches prior gene therapy launches: Zolgensma (Novartis, spinal muscular atrophy), Luxturna (Spark, inherited blindness), and Skysona (Bluebird, cerebral adrenoleukodystrophy) all faced years-long ramps limited by treatment capacity, patient identification, and payer reimbursement rather than by clinical efficacy.

The real competitor is not Lyfgenia. It is the status quo. Most SCD patients are managed with hydroxyurea, blood transfusions, and, more recently, Oxbryta (voxelotor, Pfizer). These are cheaper, simpler, and reversible. Casgevy requires patients to accept chemotherapy conditioning, weeks of hospitalization, and permanent infertility risk in exchange for a one-time cure whose durability beyond five years is still being monitored under FDA-mandated 15-year follow-up studies.

Valuation: VRTX vs CRSP

This is where the analysis gets uncomfortable for CRISPR Therapeutics bulls. Vertex at $477 trades at roughly 25x forward earnings on a base of nearly $12 billion in annual revenue. Casgevy is a rounding error for Vertex. The investment case for VRTX rests on the cystic fibrosis franchise, the Journavx pain launch, the vanzacaftor next-gen CF pipeline, and, further out, the inaxaplin kidney disease program. Casgevy is upside, not the core thesis.

CRISPR Therapeutics at $46.54 is a different animal. At a $4.2 billion market cap, CRSP is being valued almost entirely on Casgevy’s future revenue plus the next-generation CAR-T pipeline. If Casgevy hits the William Blair estimate of $132 million to CRISPR in 2026, that is a 32x price-to-sales multiple. For comparison, BioMarin (BMRN), a profitable rare-disease company with $2.5 billion in annual revenue, trades at roughly 8x P/S. Sarepta (SRPT), the gene-therapy comp with Elevidys revenue ramping, trades near 10x P/S on $2.2 billion in revenue. CRSP is being priced at 3 to 4x the multiples of revenue-generating gene-therapy peers.

The justification has to come from the pipeline. CRISPR Therapeutics’ next-generation allogeneic CAR-T candidates are CTX112 (targeting CD19, with RMAT designation in relapsed follicular lymphoma and marginal zone lymphoma) and CTX131 (targeting CD70, in solid tumors and T-cell lymphomas). Both incorporate novel potency edits, knockout of Regnase-1 and TGFBR2, designed to enhance CAR T expansion and reduce exhaustion. CTX112 has also expanded into autoimmune disease, with trials in systemic lupus erythematosus, systemic sclerosis, and inflammatory myositis. The autoimmune angle is where the platform thesis lives, given the early but striking data from autologous CD19 CAR-T in lupus remission.

But allogeneic CAR-T is a crowded field. Allogene Therapeutics (ALLE), Cellectis (CLLS), and Crispr’s own CTX110 and CTX130 predecessors struggled to show durable efficacy. CTX112 and CTX131 are improvements, but the bar for off-the-shelf CAR-T remains high, and the competitive field includes well-funded autologous competitors like Gilead/Kite and Bristol Myers Squibb.

The Risks

Three specific risks define the downside. First, treatment capacity. If the ATC network does not expand materially, the 500-patient initiation funnel will stall at the collection and infusion stages. Vertex needs to roughly double ATC throughput to hit the $344 million Casgevy estimate. Second, payer reimbursement. SCD disproportionately affects Black Americans, and the majority of patients are on Medicaid. CMS coverage exists, and Vertex has outcomes-based agreements, but prior authorization friction and state-level Medicaid variability remain real drags on conversion speed. Third, durability and safety. Casgevy is only about five years old in the clinic. The FDA requires 15-year follow-up for off-target editing and insertional mutagenesis. Any safety signal in long-term follow-up would be catastrophic for the stock and for the broader CRISPR therapy sector.

The Verdict

Vertex at $477 is a hold. Casgevy is optionality on top of a cystic fibrosis monopoly, and the Journavx launch adds a second growth driver. The valuation is full but defensible. You are paying for execution, not for a binary catalyst.

CRISPR Therapeutics at $46.54 is a speculative bet on the pipeline, not on Casgevy. The Casgevy revenue ramp alone does not justify a $4.2 billion market cap at a 32x P/S multiple when Sarepta trades at 10x with 10x the revenue. The bull case requires CTX112 or CTX131 to deliver differentiated clinical data in autoimmune disease or solid tumors that justifies a platform premium. The Q2 2026 earnings on August 3 will clarify whether Casgevy is on track for the $344 million 2026 estimate, but the real catalyst is the next CTX112 autoimmune data readout. If you own CRSP, you own the pipeline, not the approved drug. Price accordingly.